have demonstrated that the combination of the CXCR4 antagonist LY2510924 and the FLT3 inhibitor quizartinib reversed the stroma-mediated resistance against the FLT3 inhibitor and induced the mobilization and differentiation of AML cells in mice, resulting in enhanced anti-leukemia effects (32). The gene discussed is FLT3; the disease is acute myeloid leukemia.